ClinicalTrials.gg
Not yet recruitingNCT07420439Updated Aug 11, 2026

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

A Phase 2 interventional study of Paclitaxel and Bevacizumab in Non Small Cell Lung Cancer Metastatic and Interstitial Lung Disease (ILD), sponsored by Intergroupe Francophone de Cancerologie Thoracique. Not yet recruiting at 31 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Intergroupe Francophone de Cancerologie Thoracique · Phase 2, Interventional, and Treatment

How we know · 17 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Lung Diseases, Interstitial with a site in France — 37 open to participants now, 48 under way, 15 of them phase 3. Lung Diseases, Interstitial · France.

Planned enrollment
33rd of 60
108 · median 138
Started
2026
with 14 others
Phase 2
11 of 90
4 open now
Primary completion
2028-08
later than 28 of 47 live
Registered
84th of 90
by date

Among the 90 studies in Lung Diseases, Interstitial with a site in France, this one is the 33rd largest by planned enrollment of the 60 interventional ones that give a count, is one of 15 that started in 2026, is one of 11 in phase 2, reaches primary completion later than 28 of the 47 other live ones, and was the 84th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

37 of the 90 studies in Lung Diseases, Interstitial with a site in France are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Lung Diseases, Interstitial with a site in France, or all of them as a file.
02

Study summary

Lung cancer is a leading cause of cancer-related death worldwide. Interstitial Lung Diseases are closely associated with lung cancer either as complications or comorbidities to be considered for treatment.

Recently, a survey concerning the management of lung cancer in patients with ILDs was conducted by the Interstitial Lung Diseases and Thoracic Oncology Assemblies of the European Respiratory Society. Out of 494 practitioners, mostly pulmonologists, this survey showed that the majority of metastatic patients with pulmonary fibrosis would not be treated (69%), but that 25% and 31% of clinicians would offer chemotherapy or immunotherapy, respectively.

The systemic therapy is not clearly codified. There is a risk of worsening of ILDs with most of the treatments used in lung cancer including surgery, radiation therapy or certain systemic therapies. The Japanese Society of Pneumology has recently published proposals for care. However, the Asian population is unique in its incidence of ILDs and the frequency of drug toxicities and these recommendations may not be relevant for other populations. Thus, data are still needed to validate carboplatin and weekly paclitaxel as the best regimen for first-line treatment of NSCLC patients with ILD in a caucasian population.

In 2nd line setting, immune checkpoint blocker (ICB) in monotherapy or associated with chemotherapy has become an essential part of the therapeutic arsenal in advanced NSCLC. Several agents have been shown to be superior to docetaxel, following platinum-based chemotherapy failure, and have resulted in several marketing authorizations for PD-1 inhibitors (nivolumab, pembrolizumab) and PD-L1 inhibitors (atezolizumab).

The long-term benefits of using ICBs as a second-line therapy are now clear. Survival at 5 years is 10% higher than that obtained with docetaxel alone.

The safety profile is well known in particular with a risk of pulmonary toxicity. It should be noted that in most trials, patients with ILDs were not included. Therefore, we do not have trial data from these pivotal trials in patients with concomitant ILD.

Two prospective studies are available on the use of nivolumab in the second-line setting in patients with idiopathic ILDs. The first, in an Asian population, included 6 patients. It showed an interesting response rate of 50% without grade III or IV pulmonary toxicity or worsening of at 12 weeks.

Following this, the same team proposed a multicenter phase 2 study. Included patients had mild ILDs (VCf >80%) and were treated with nivolumab in 2nd line. The primary objective was PFS at 6 months. 18 patients were treated. 3 patients developed toxicity leading to discontinuation of nivolumab including 2 patients with grade 2 pneumonitis. PFS at 6 months was 56%, response rate was 39% and disease control achieved for 72% of patients.

In a recent prospective study in Asia, atezolizumab was administered to patients with moderate IPF and advanced NSCLC. The study was stopped prematurely due to a high incidence of inflammatory pneumonitis.

Thus, data are still needed to assess the safety of ICB in NSCLC patients with ILD in second line setting.

03

Conditions studied

  • Non Small Cell Lung Cancer Metastatic
  • Interstitial Lung Disease (ILD)

Keywords

  • NSCLC
  • ILD
  • chemotherapy
  • immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for both parts:

  • Informed, written and signed consent: Patients must have signed and dated the written form approved by the ethics committee in accordance with the legal and institutional framework. It must have been signed before protocol-related procedures that are not part of normal patient management are performed. Patients should be willing and able to adhere to the schedule of visits, treatment and laboratory tests.
  • Patients with radiological ILDs. All cases should be presented in a multidisciplinary board dedicated to ILD to confirm eligibility. In centres without a local multidisciplinary board dedicated to ILD, the national multidisciplinary board CAPID can be used.
  • NSCLC proven histologically. Cytological evidence is allowed if a cytoblock has been prepared.
  • Age ≥ 18 years old.
  • Performance status ≤ 2.
  • Stage IIIB or IIIC non-eligible to radiation therapy or IV (8th TNM classification, UICC 2015). For other less advanced stages but rejected for any local treatment, possible inclusion discussion with the sponsor.
  • Disease measurable according to criteria 1.1 per investigator assessment.
  • Adequate biological function: ≥ 45 mL/min (Cockroft or or CKD-epi); neutrophils ≥ 1500/mm3; ≥ 100,000/mm3; ≥ 9 g/dL; liver enzymes\< 3x except for patients with liver (\< 5x ULN); total ≤ 1.5x ULN except for patients with proven Gilbert's syndrome (≤ 5x ULN) or patients with liver metastases (≤ 3.0 mg/dL).
  • of at least 12 weeks.
  • For female patients of and patients with a partner of childbearing potential, agreement (by the patient and/or partner) to use one or more highly effective (failure rate \< 1% per year when used correctly and regularly) and to continue using it for 7 months after the last dose of treatment. Men should not donate their sperm for the duration of the study and for at least 7 months after the last dose of treatment. Oral contraception should always be combined with another method of contraception because of potential interactions with treatment. Patients should always use a condom.
  • Patient covered by national health insurance.
  • Protected adults may participate in the study if they can make decisions regarding their medical treatment in accordance with the guardianship judgment.

Inclusion Criteria for part:

  • Patient must be treatment naive for advanced or metastatic disease. Treatment for non-metastatic stage is not considered as a line if there is a time interval of at least 6 months between the last dose of treatment for non-metastatic stage and recurrent disease.
  • ILD criteria: any type of ILD and any level of severity are allowed Inclusion criteria specific to second-line part
  • Patients must have received one but no more than one platinum-based therapy for advanced or metastatic disease. Treatment for non-metastatic stage is not considered as a line if there is a time interval of at least 6 months between the last dose of treatment for non-metastatic stage and recurrent disease.
  • ILD severity criteria: Patients with ILDs with mild to moderate alteration of pulmonary function, defined by Forced Vital Capacity (FVC) ≥ 50% of the predicted value AND DLCO≥ 35% of the of the predicted value. All cases should be presented in a multidisciplinary board dedicated to ILD to confirm eligibility. In centers without a local multidisciplinary board dedicated to ILD, the national multidisciplinary board CAPID can be used.
  • ILD type criteria: Patient with idiopathic interstitial pneumonia (including IPF and NSIP) or secondary ILDs (including pneumonia, pneumoconiosis, radiation pneumonitis) could be included. Will be excluded patients with ILDs secondary to connective tissue disease, vasculitis or granulomatosis (including but not limited to granulomatosis with polyangiitis, rheumatoid arthritis, Sjogren's syndrome, scleroderma, myositis/dermatomyositis, anti-synthetase syndrome). For sarcoidosis and for Interstitial pneumonia with features (IPAF) inclusion could be confirmed based on a case-by-case discussion with the sponsor.
  • Available results for Immunoassay including antinuclear antibodies tested by immunofluorescence, rheumatoid factor, anti-CCP, Anti-dsDNA, Anti-Ro (SS-A), Anti-La (SS-B), Anti-ribonucleoprotein, Anti-Smith, Anti-topoisomerase (Scl-70), Anti-tRNA synthetase (Jo-1, PL-7, PL-12, Anti-PM-Scl, Anti-MDA-5), ANCA.

Exclusion criteria for both parts

  • Small cell lung cancer or tumor with mixed histology including a small cell component.
  • Known EGFR activating mutation or ALK or ROS rearrangements. Inclusion of patients with any other oncogene addiction (excluding KRAS mutations) should be discussed with the sponsor on a case-by-case level.
  • History of cancer or cancer active within 3 years except those with a negligible risk of metastasis or death treated curatively (such as adequately treated cervical cancer in situ, basal or squamous cell skin cancer or ductal carcinoma in situ curatively treated. For other types of cancer, please contact the IFCT). Patients with a history of prostate cancer in the last 5 years may be included in cases of localized prostate cancer of good prognosis according to the Amico classification (≤ T2a and Gleason score ≤ 6 and PSA ≤ 10 ng/mL) and if they have been treated curatively (surgery or radiotherapy ± hormone therapy, without chemotherapy).
  • Acute exacerbation of interstitial lung disease less than 6 months ago. Exclusion criteria specific to first line part
  • Previous systemic therapy (including but not limited to chemotherapy, targeted therapy, immunotherapy). Treatment for non-metastatic stage is not considered as a line if there is a time interval of at least 6 months between the last dose of treatment for non-metastatic stage and recurrent disease.

Exclusion criteria specific to second line part

  • History of severe allergy, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the pembrolizumab/nivolumab formulation.
  • Diagnosis of interstitial lung disease with manifestations of autoimmunity (IPAF) according to ATS/ERS criteria39 Inclusion may be considered on a case-by-case basis following discussion with the sponsor.
  • More than one line of treatment.
  • Any prior immunotherapy.
  • History of autoimmune disease, connective tissue disease, vasculitis or granulomatosis associated with but not limited to myasthenia gravis, myositis, autoimmune hepatitis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis or glomerulonephritis.
  • Diagnosis of ILDs due to connective tissue disease, vasculitis or granulomatosis including but not limited to granulomatosis with polyangiitis, rheumatoid arthritis, Sjogren's syndrome, scleroderma, myositis/dermatomyositis, anti-synthetase syndrome. For sarcoidosis and for Interstitial pneumonia with autoimmune features (IPAF) inclusion could be confirmed based on a case-by-case discussion with the sponsor.
  • therapy > 10 mg daily oral prednisone or equivalent.
  • therapy within two weeks prior to randomization.
  • Patients who have had major surgery ≤ 3 weeks before randomization.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    First line part (monoarm)

    Carboplatine + paclitaxel + bevacizumab for up to 4 cycles

    Drug: Paclitaxel · Drug: Bevacizumab · Drug: Carboplatin

  • Active comparator
    2nd line part - Arm A

    Paclitaxel with or without bevacizumab or pemetred or vinorelbine (gemcitabine is possible but not recommended)

    Drug: Paclitaxel · Drug: Bevacizumab · Drug: Pemetrexed · Drug: Vinorelbine · Drug: Gemcitabine

  • Experimental
    2nd line part - Arm B

    Nivolumab of pembrolizumab

    Drug: Nivolumab · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. 1st line part: disease Control Rate at 8 weeks

    Assessed by investigators according to RECIST 1.1.

    Time frame: 8 weeks from date of inclusion

  2. 2nd line part: Treatment related respiratory worsening leading to discontinuation of treatment during the first 6 months

    Time frame: 6 months from randomisation

Secondary outcomes

  1. Progression-free survival

    Time frame: About 6 months

  2. Duration of response

    Time frame: About 6 months

  3. Overall Survival

    Time frame: About 20 months

  4. Best overall response

    Time frame: About 6 months

  5. 1st line part: Disease control rate at 8 weeks

    Assessed by Independent Central Review

    Time frame: 8 weeks

  6. 2nd line part: Disease control rate at 8 weeks

    Assessed by Investigators

    Time frame: 8 weeks

  7. Progression-free survival according to ILDs pattern on CT scan

    Time frame: About 6 months

  8. Duration of response according to ILDs pattern on CT scan

    Time frame: About 6 months

  9. Overall Survival according to ILDs pattern on CT scan

    Time frame: About 20 months

  10. Best overall response according to ILDs pattern on CT scan

    Time frame: About 6 months

  11. Progression-free survival according to ILDs severity (FVC/DLCO)

    Time frame: About 6 months

  12. Duration of response according to ILDs severity (FVC/DLCO)

    Time frame: About 6 months

  13. Overall Survival according to ILDs severity (FVC/DLCO)

    Time frame: About 20 months

  14. Best overall response according to ILDs severity (FVC/DLCO)

    Time frame: About 6 months

  15. Respiratory evolution (number of exaxerbations of ILD) with or without anti-fibrosing treatment

    Time frame: About 6 months

  16. Progression-free survival with or without anti-fibrosing treatment

    Time frame: About 6 months

  17. Duration of response with or without anti-fibrosing treatment

    Time frame: About 6 months

  18. Overall Survival with or without anti-fibrosing treatment

    Time frame: About 20 months

  19. Best overall response with or without anti-fibrosing treatment

    Time frame: About 6 months

  20. Overall health status assessed using the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire

    Time frame: About 6 months

  21. Incidence, nature, and severity of adverse events

    Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 6.0

    Time frame: About 6 months

  22. 2nd ine part: Incidence, nature, and severity of immune related adverse events

    Graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 6.0

    Time frame: About 6 months

07

Study locations

31 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Aug 2028, 23 months later.

Of 53 phase 2 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 71. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 19, 2026
StartEst.
Sep 15, 2026
Primary completionEst.
Aug 15, 2028
CompletionEst.
Nov 15, 2028
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07420439
Lead sponsor
Intergroupe Francophone de Cancerologie Thoracique
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Aug 15, 2028 (estimated)
Completion
Nov 15, 2028 (estimated)
Last update
Aug 11, 2026

Study contacts

Contact IFCT
Contact
contact@ifct.fr
+33 1 56 81 10 45

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Paclitaxel · Bevacizumab · Carboplatin · Nivolumab · Pembrolizumab

Start the discussion